Interestingly, while lenalidomide has exhibited anti-tumor activity against ABC-DLBCL cell lines only, avadomide has shown direct apoptotic activity against both GCB- and ABC-DLBCL subtypes, attributed to enhanced transcription of interferon (IFN)–stimulated genes and associated anti-tumor activity but independent of IFN-α, -β and -y production and secretion by malignant B cells [23]. This evidence concerns the gene IFNA1 and diffuse large B-cell lymphoma.